Table 1

Patient characteristics

Serum CEA (ng/ml)
Patient no.Age (yr)/sexDosage (pfu)Performance statusaPrimary siteMetastatic diseasePrestudyWeek 8Responseb
155 /M1071ColonLiver29109P
266/M1071RectalLiver, lung154288P
359/M1070RectalLiver, lung725P
463/M1071ColonLymph nodes52P
565/M1071CholangiocarcinomaPeripancreatic21P
670/F1070ColonLymph nodes188166S
773/M1071RectalLiver4191P
864/F1071ColonLymph nodes180227P
944/M1072CholangiocarcinomaLiver, lymph nodes7790P
1077/M1072ColonLiver33586820P
1177/F1082ColonLiver, abdomen wall4545P
1249/F1081ColonLiver, lung103168P
1375/M1080ColonLiver, adrenal17762933P
1462/M1081RectalLiver, peritoneal554919P
1542/M1081ThyroidMediastinum, bone667969S
1666/F1081RectalLiver, lung, nodes3944S
1753/F1080BreastPeritoneum3342P
1871/M1081ColonLiver18139P
1962/M1081GastroesophagealLymph nodes11S
2067/M1081ColonLiver, lung306392P
  • a Performance status based on the Eastern Cooperative Oncology Group scale (0–4).

  • b Response based on off-study evaluation on day 57. P, progressive disease; S, stable disease.